196 related articles for article (PubMed ID: 32533671)
1. Hospital Pharmacy Compounding against COVID-19 pandemic.
Alonso-Herreros JM; Berisa-Prado S; Cañete-Ramírez C; Dávila-Pousa C; Flox-Benítez MDP; Ladrón de Guevara-García M; López-Cabezas C; Martín de Rosales-Cabrera AM; Ramos-Martínez B
Farm Hosp; 2020 Jun; 44(7):49-52. PubMed ID: 32533671
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical management of the COVID-19 pandemic in a mid-size hospital.
Corregidor-Luna L; Hidalgo-Correas FJ; García-Díaz B
Farm Hosp; 2020 Jun; 44(7):11-16. PubMed ID: 32533662
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical care in hospitalized patients. (Management of the COVID-19 pandemic crisis. A new challenge for pharmacy services).
Sevilla-Sánchez D; Tuset-Creus M
Farm Hosp; 2020 Jun; 44(7):28-31. PubMed ID: 32533666
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 Pandemic. New challenge for hospital pharmacy services.
Bermejo-Vicedo T; Queralt Gorgas M
Farm Hosp; 2020 Jun; 44(7):3-4. PubMed ID: 32533660
[No Abstract] [Full Text] [Related]
6. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
7. Pharmacy Department management and organization.
Herranz-Alonso A; Rodríguez-González CG; Sarobe-González C; Álvarez-Díaz A; Sanjurjo-Sáez M
Farm Hosp; 2020 Jun; 44(7):5-10. PubMed ID: 32533661
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
10. BET 1: Lopinavir-ritonavir and COVID-19.
Dolan D; Ingham J; Baombe J
Emerg Med J; 2020 Jul; 37(7):450-451. PubMed ID: 32616658
[No Abstract] [Full Text] [Related]
11. Hospital Pharmacy Service: Facing the logistics of medicines procurement.
Palomar-Fernández C; Álvarez-Díaz A
Farm Hosp; 2020 Jun; 44(7):17-20. PubMed ID: 32533663
[TBL] [Abstract][Full Text] [Related]
12. The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.
Danion F; Ruch Y; Fourtage M; Kaeuffer C; Greigert V; Lefebvre N; Muller J; Nai T; Hansmann Y
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513798
[No Abstract] [Full Text] [Related]
13. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
[TBL] [Abstract][Full Text] [Related]
14. Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate.
Iwasaka S; Shono Y; Tokuda K; Nakashima K; Yamamoto Y; Maki J; Nagasaki Y; Shimono N; Akahoshi T; Taguchi T
J Infect Chemother; 2020 Dec; 26(12):1319-1323. PubMed ID: 32893123
[TBL] [Abstract][Full Text] [Related]
15. Clinical research in hospital pharmacy during the fight against COVID-19.
Castro-Balado A; Varela-Rey I; Bandín-Vilar EJ; Busto-Iglesias M; García-Quintanilla L; Mondelo-García C; Fernández-Ferreiro A
Farm Hosp; 2020 Jun; 44(7):66-70. PubMed ID: 32533675
[TBL] [Abstract][Full Text] [Related]
16. Favourable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression.
Sieni E; Pegoraro F; Casini T; Tondo A; Bortone B; Moriondo M; Azzari C; Galli L; Favre C
Br J Haematol; 2020 Jun; 189(6):e222-e224. PubMed ID: 32369615
[No Abstract] [Full Text] [Related]
17. Psychopharmacology of COVID-19.
Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of antiviral drugs may be the reason for recovered COVID-19 patients testing positive again.
Wu F; Zhang W; Zhang L; Wang D; Wan Y
Br J Hosp Med (Lond); 2020 Apr; 81(4):1-2. PubMed ID: 32339007
[No Abstract] [Full Text] [Related]
19. Early experience with remdesivir in SARS-CoV-2 pneumonia.
Durante-Mangoni E; Andini R; Bertolino L; Mele F; Florio LL; Murino P; Corcione A; Zampino R
Infection; 2020 Oct; 48(5):779-782. PubMed ID: 32418190
[TBL] [Abstract][Full Text] [Related]
20. Specialized pharmaceutical care in social health centers in the times of COVID-19.
Peris-Martí JF; Bravo-José P; Sáez-Lleó C; Fernández-Villalba E
Farm Hosp; 2020 Jun; 44(7):43-48. PubMed ID: 32533670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
